Antithrombotic Drug Management and Bleeding Risk in High-Risk Endoscopic Procedures

Supplementary Material for a multicenter retrospective observational study investigates the association between peri-procedural antithrombotic drug management and 30-day bleeding outcomes. The dataset includes records from high-risk upper and lower gastrointestinal procedures, such as 1365 esophageal ESDs and 23,326 colonic polypectomy/EMRs. The study was published on figshare by karger admin and last updated on 2026-05-15.

Use Cases

• Compare bleeding risk differences between antithrombotic drug management strategies based on the categories of continuation, discontinuation, and replacement.
• Analyze procedure-specific bleeding rates for upper-GI versus lower-GI endoscopic procedures mentioned in the description.
• Evaluate the 30-day post-procedural bleeding outcomes for specific drug groups like aspirin, thienopyridine, warfarin, and DOACs.
• Assess the absolute risk differences in bleeding events, reported to be within 10% for upper-GI and 5% for lower-GI procedures.

Strengths

• Multicenter study design, likely incorporating data from multiple institutions.
• Includes a large number of procedure instances, such as 5,391 gastric ESDs and 23,326 colonic polypectomy/EMRs.
• Explicitly categorizes antithrombotic drug management into continuation, discontinuation, and replacement for analysis.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect temporal or institutional bias inherent to a retrospective study from specific centers.

Provenance

Source

figshare admin karger

Collection Method

Multicenter retrospective cohort study on high-risk endoscopic procedures.

Freshness

Last updated 2026-05-15 07:55:11; freshness should be verified.